Oncode Institute

Outsmarting cancer, impacting lives

Oncode Institute aims to outsmart cancer and impact lives. To achieve this, Oncode focuses on three pillars: excellent research, intensive collaboration and powerful valorization. The research strategy is focused on understanding the basic mechanisms of cancer to realize the ultimate goal: safer and more effective medical solutions as well as personalized precision diagnostics. Oncode brings together excellent cancer researchers in The Netherlands: 61 research groups from 12 different Dutch research institutes collaborate on 6 interdisciplinary research themes. To speed up the translation of scientific discoveries into clinical applications, Oncode has a dedicated team of specialists to support scientists in the valorization process.

icon_Hands 12 partner institutions

61 Principal Investigators

icon_Money € 120 million

funding for 5 years

About Oncode Institute

Over the past decades, the scientific and medical community has made tremendous progress in understanding and treating cancer. However, the disease still has a large burden on society as cancer has become the primary cause of death in The Netherlands. In an effort to address this unmet clinical need, Dutch cancer researchers have joined forces within Oncode Institute. To come up with new avenues for treatment and diagnosis, Oncode focuses on better understanding the fundamental mechanisms of cancer biology. With the ultimate goal to improve long-term survival and the quality of life of patients.Oncode serves as a platform for excellent cancer researchers in The Netherlands to collaborate, share knowledge, expertise and technology. As a virtual Institute it stimulates scientific freedom and offers dedicated support to optimize the translation of fundamental insights into clinical applications. Outsmarting cancer, impacting lives.  Visit the Oncode website for more information about the project.

Over 800+ Oncode researchers working under a single strategy that focuses on six different research themes:

  1. Development of novel technologies
  2. Understanding the critical drivers of tumour growth and the causes of resistance
  3. Analysis of network perturbations in tumours and tumour-host interactions
  4. Causes and consequences of genetic instability
  5. Identification of critical drug combinations and biomarkers for personalized cancer treatments
  6. Mobilising immune defence

Oncode invests heavily in the transfer of results from fundamental research into clinical applications. A team of dedicated specialists will help Oncode researchers with valorization of their findings. Furthermore, Oncode offers tailored training programs for affiliated researchers and actively invests in diversity through its Young Female Investigator program. 

Accelerating innovation by partnership management

Based on its broad experience with partnership management and communication, Lygature has become a partner of Oncode. Lygature supports Oncode Institute with the following services:

  • Program management
  • Communication & external affairs
  • Finance & IT-infrastructure
  • Patient engagement

Lygature together with

Project updates

  • Icon of a doctor

    Oncode funds project on clinical implementation of the MeD-seq assay

    Oncode created the clinical Proof-of-Concept fund (cPoC) to support the clinical translation of Oncode’s fundamental research. We are pleased to announce that the 11th grant within the cPoC programme has been awarded to Oncode Investigator Joost Gribnau (Erasmus MC). Together with colleagues, he will work on the clinical implementation of their recently developed MeD-seq assay. The goal of the project is to deliver proof of concept of the clinical applicability of their MeD-seq assay, which is able to detect tumor-specific epigenetic patterns in the circulating cell-free DNA in the blood of patients. The researchers will evaluate whether this assay can predict early recurrence in colorectal cancer patients with surgically removable liver metastases.

    Read more

  • A crisis calls for community: how three Oncode Investigators help find solutions for COVID-19

    For more than half a year now, finding solutions to solve the current COVID-19 crisis is a priority - not only for the Netherlands, but for the entire world. With labs closed and the entire country in lockdown, the urgency and the pressure became almost tangible. In the midst of the chaos, Oncode Investigators Marvin Tanenbaum, Hans Clevers (both Hubrecht Institute) and Lude Franke (UMC Groningen) decided to put their knowledge and skills to good use.

    Read more

  • Alain Kummer

    Oncode Institute appoints Alain Kummer as its new Managing Director

    Oncode Institute announced today that its Supervisory Board has appointed Alain Kummer as Managing Director per September 1st, 2020. On the same day, Ton Rijnders, Oncode’s General Director, will step down from his position. As of September 1st, the new Oncode Managing Board will consist of Geert Kops (Scientific Director and Head of the Institute), Chris De Jonghe (Valorization Director) and Alain Kummer (Managing Director).

    Read more